Elitek (rasburicase) NDC 0024-5151

NDC codes

FDA NDC Directory

Product NDC (as listed)0024-5151Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00024-5151Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0024-5151-75	00024515175	1 KIT in 1 CARTON (0024-5151-75) * 5 mL in 1 VIAL, SINGLE-USE (0024-5155-74) * 5 mL in 1 AMPULE (0024-5153-74)Marketed from Jun 1, 2006

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Elitek
Generic name (nonproprietary): rasburicase
Dosage form: Kit
Labeler: Sanofi-Aventis U.S. LLC
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 103946
Marketing start: Jun 1, 2006
Listing expires: Dec 31, 2027
Identifiers: Product ID 0024-5151_424aedac-a777-40a3-b6d3-a8fe7e305b79SPL ID 424aedac-a777-40a3-b6d3-a8fe7e305b79SPL set ID 0ae10bc4-6b65-402f-9db5-2d7753054922RxCUI 1790344, 1790347, 1790349, 1790351

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N400024515175 followed by a unit qualifier and the quantity

Package 00024-5151-75. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 30, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Elitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. Elitek is a recombinant urate-oxidase indicated for initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. ( 1 ) Limitations of use: Elitek is indicated only for a single course of treatment. ( 1 ) Limitations of Use Elitek is in…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 103946

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 103946
Product	Strength	Form · route	Labeler	Product NDC
Elitekrasburicase	—	Kit	Sanofi-Aventis U.S. LLC	0024-5150